



Cite this: *RSC Adv.*, 2017, 7, 51640

Synthesis and biological evaluation of 1-(2-(adamantane-1-yl)-1*H*-indol-5-yl)-3-substituted urea/thiourea derivatives as anticancer agents†

Hongyu Hu,^{‡,ab} Chunrong Lin,^{‡,a} Mingtao Ao,^{‡,a} Yufen Ji,^a Bowen Tang,^a Xiaoxiao Zhou,^a Meijuan Fang,^{‡,a} ^{*,a} Jinzhang Zeng^{*,a} and Zhen Wu^{*,a}

The indole ring, adamantane, and urea groups are important components of bioactive molecules. The orphan nuclear receptor Nur77 as a unique transcription factor encoded by an immediate early gene is a potential therapeutic target for cancer treatment. We synthesized a series of 1-(2-(adamantane-1-yl)-1*H*-indol-5-yl)-3-substituted urea/thiourea derivatives and identified which of these potential anticancer candidates could modulate the expression and activity of Nur77. The synthesized compounds were initially evaluated for their anti-proliferative activity against H460 lung cancer cells, HepG2 liver cancer cells, and MCF-7 breast cancer cells. Major compounds were found to be active against these tested cancer cell lines. The compounds with IC₅₀ values down to 20 μM exhibited selective cytotoxicity effects on the human lung cancer cell line (H460) and the normal lung cell line (MCR-5). Compounds **7n**, **7s**, and **7w** induced Nur77-expression in a time- and dose-dependent manner in H460 cells. Compounds **7n** and **7s** strongly induced Parp cleavage in H460 cells, but **7w** resulted in a slight induction of apoptosis. The apoptotic effect of **7s** was largely inhibited when the Nur77 was knocked down by shRNA. This indicated that Nur77 served as a critical mediator for the anticancer action of **7s**. The molecular docking study between Nur77 and **7s** revealed that compound **7s** exhibited a promising binding affinity with Nur77. These findings will provide a direction for the developing Nur77 regulator as anticancer agents.

Received 24th July 2017
 Accepted 18th October 2017

DOI: 10.1039/c7ra08149a

rsc.li/rsc-advances

1. Introduction

Nur77 (also known as NR4A1, NGFI-B, or TR3) is an orphan member of the nuclear receptor super-family that regulates the expression of genes involved in multiple physiological and pathological processes.¹ As an immediate-early response gene, Nur77 expression could be induced by various stimuli, including mitogenic and apoptotic signaling.^{2–4} Nur77 plays a role in cell survival, cell death, and is implicated in various malignancies.^{3–11} Nur77 is upregulated in gastric tumorsphere cells,¹² non-small cell lung cancer (NSCLC) tissues and cells,¹³ and colon tumors.^{14,15} Previous studies have found that Nur77 is often overexpressed in tumour tissues, when compared to the para-carcinoma normal tissues.¹⁶ Nur77 is a potentially promising drug target for cancer treatment. A number of anticancer compounds with diverse chemical structures, such as

acetylshikonin analogue SK07,¹⁷ DIM-C-pPhOCH₃,¹⁸ Vit K2,¹⁹ diindolylmethane analog,²⁰ Csn-B,²¹ cardenolides H9 and ATE-i2-b4,²² AmB-NC,²³ CD437,^{10,24} *n*-butylidenephthalide,²⁵ and norcantharidin²⁶ have been identified as critical modulators of the genomic or the nongenomic pathways of Nur77. These findings suggest that Nur77 is a critical and meaningful drug target. Thus, we are interested in exploring a novel Nur77 regulator.

The indole ring has been proven to be a critical pharmacophore in many chemotherapeutics.^{27–29} The introduction of different side chains around the indole nucleus has resulted in the development of various therapeutic drugs, including obatoclax,³⁰ and sunitinib,³¹ as well as many lead compounds that boast a wide variety of biological activities. Modifying the 2nd and 5th positions of the indole moiety has been shown to be crucial for receptor binding and activation.³² The adamantane derivatives were initially used as an antiviral drug (adamantane) to combat various strains of the flu,³³ to treat parkinson's disease (adapalene, dopamantine, memantine, rimantadine and tromantadine), and as dipeptidyl peptidase-4 (DPP-4) inhibitors (saxagliptin, and vildagliptin) for the treatment of type 2 diabetes.³⁴ Some other clinical drugs like sorafenib are urea derivatives of the indole pharmacophore.

Based on the biological profiles of the indole ring, the adamantane, the urea group, and the continuation of our research

^aFujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, South Xiang-An Road, Xiamen, 361102, China. E-mail: wuzhen@xmu.edu.cn; jzzeng@xmu.edu.cn; fangmj@xmu.edu.cn; Fax: +86-592-2189868; Tel: +86-592-2189868

^bCollege of Xingzhi, Zhejiang Normal University, Jinhua 321004, China

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c7ra08149a

‡ The first two authors are co-first authors.



work on synthesis of indole derivatives,³² we initially synthesized a series of novel 1-(2-(adamantan-1-yl)-1*H*-indol-5-yl)-3-substituted urea/thiourea derivatives and evaluated their anti-cancer activity on cancer cell line (HepG2), and breast cancer cell line (MCF-7) by MTT assay. The compounds that exhibited prominent activity against tested cancer cell lines with IC₅₀ down to 20 μM were subsequently tested for their cytotoxicity on normal cell lines (MCR-5 and LO2) as well as their effect on Nur77 activation in H460 cells. Those compounds that had Nur77 activation ability in H460 cells and also exhibited selective cytotoxicity on tumours and normal cell lines which were isolated from the same tissue, were used to further explore their induction of apoptosis in various tumour cell lines and normal NIH-3T3 cells. Compounds **7s**, **7n** and **7w** induced apoptosis in H460 cells. This ability for apoptosis induction was closely associated with their Nur77 activation. The RNA interference technology and the molecular docking study were performed to explore the molecular mechanisms that mediate the induction of apoptosis by this specific class of compounds.

2. Results and discussion

2.1. Syntheses of the designed compounds


The general chemistry for the synthesis of **7a–7y** and **9a–9o** is outlined in Scheme 1. First, we synthesized 2-adamantane-1*H*-indol-5-amine (**5**). The treatment of 1-adamantanecarboxylic acid chloride (**1**) with *o*-toluidine resulted in *N*-*o*-tolylcycloadamantanecarboxamide (**2**),³² and 2.5 M of *n*-butyl lithium in hexane was then added dropwise to obtain the corresponding 2-adamantane-1*H*-indole (**3**).³² Compound **5** was formed through the nitrification and catalytic hydrogenation of compound **3**.³⁵ 5-Isocyanato-1*H*-indole-adamantane (**6**) was obtained by reacting compound **5** with triphosgene.³⁶ The intermediate **6** was subjected to reactions with various amines in order to produce compounds **7a–7y**. The reaction of compound **5** with triethylenediamine (Dabco), CS₂, and bis(trichloromethyl)carbonate (BTC) resulted in 5-isothiocyanato-1*H*-indole-adamantane (**8**).³⁷ Compound **8** was converted into compounds **9a–9o** by

treatment with the corresponding amine. The structures of the target compounds were confirmed with ¹H-NMR, ¹³C-NMR, and high-resolution mass spectrometry (HRMS). The purities of the target compounds were evaluated with high-performance liquid chromatography with diode-array detection (HPLC-DAD) performed at 254 nm and 280 nm.

2.2. Anti-proliferative activities of synthesized compounds in various cancer cells and their structure–activity relationship

The synthesized compounds were evaluated for their anti-proliferative activities against various human cancer cell lines including H460, HepG2 and MCF-7. The concentration required for 50% inhibition of cell viability (IC₅₀) was calculated. The IC₅₀ values of the compounds are summarized in Tables 1 and 2. The results indicated that a majority of the synthesized compounds had a moderate anti-proliferative activity against the three human cancer cell lines. Exceptions were found in compounds **7c**, **7d**, **7e**, **7g**, **7h**, **7i**, **9c**, and **9d**. Attempts were made to establish the structure–activity relationship (SAR) among the tested compounds based on data collected from three independent experiments.












2.2.1. 1-(2-(Adamantan-1-yl)-1*H*-indol-5-yl)-3-substituted urea derivatives. Among the alkyl substituted compounds (**7a–7j**), compound **7f** with a phenethyl group and **7a** with a *t*-butyl group had the highest potency of anti-proliferative properties in H460 cells (IC₅₀ of **7f**, 0.42 ± 0.09 μM), HepG2 cells (IC₅₀ of **7f**, 0.28 ± 0.08 μM) and MCF-7 cells (IC₅₀ of **7a**, 5.16 ± 0.20 μM). The IC₅₀ values of compounds **7c**, **7d**, **7g**, and **7h** were over 100 μM for at least one of the three tested human cancer cell lines. This indicated that the introduction of a *n*-alkyl group that had more than three carbon atoms to the pharmaceutical core was unfavourable for anti-proliferative properties. Compound **7e** which contained a cycloheptyl group had no activity with IC₅₀ values up to 100 μM. Compound **7b** which had a cyclobutyl group demonstrated good anti-proliferative activity (IC₅₀, 10.0–25.0 μM). This suggested that the substitution of the cycloalkyl



Scheme 1 Synthesis of 1-(2-(substituted hydrazinecarbonyl group)-1*H*-indol-5-yl)-3-substituted urea. Reagents and conditions: (a) toluene, *o*-toluidine, K₂CO₃, r.t., 4 h; (b) *n*-BuLi, THF, 0 °C, N₂, 3 h; (c) NH₄NO₃, H₂SO₄, 0 °C, 1 h; (d) 10% Pd/C, MeOH, 70 °C, 2 h. (e) Triphosgene, THF, trimethylamine, 0 °C, 4 h; (f) R–NH₂, toluene, 60 °C, 4 h. (g) Dabco, CS₂, toluene, BTC, DCM. (h) R–NH₂, toluene, 60 °C, 4 h.



Table 1 Anti-proliferative activity of 1-(2-(adamantan-1-yl)-1*H*-indol-5-yl)-3-substituted urea 7a–7y^a

Compound	R	IC ₅₀ (μM) ± S.D.		
		H460	HepG2	MCF-7
7a		5.77 ± 0.12	5.93 ± 0.15	5.16 ± 0.20
7b		25.25 ± 1.45	15.19 ± 1.00	13.78 ± 0.98
7c		>100	34.06 ± 1.25	>100
7d		>100	>100	>100
7e		>100	>100	>100
7f		0.42 ± 0.09	0.28 ± 0.08	6.96 ± 0.12
7g		13.21 ± 0.15	1.42 ± 0.10	>100
7h		>100	>100	>100
7i		>100	>100	23.11 ± 0.52
7j		11.75 ± 0.85	22.10 ± 1.00	16.01 ± 1.02
7k		11.99 ± 0.95	13.06 ± 1.10	8.07 ± 0.85
7l		41.82 ± 2.55	75.74 ± 2.65	40.47 ± 2.89
7m		60.89 ± 4.55	18.32 ± 1.45	13.96 ± 0.65
7n		12.89 ± 1.41	22.24 ± 1.41	18.1 ± 2.18
7o		54.13 ± 2.40	17.22 ± 1.36	11.60 ± 0.65
7p		50.33 ± 2.70	72.46 ± 3.40	51.09 ± 1.70













Table 1 (Contd.)

Compound	R	IC ₅₀ (μM) ± S.D.		
		H460	HepG2	MCF-7
7q		62.82 ± 3.50	77.37 ± 3.12	56.84 ± 2.54
7r		32.30 ± 1.53	16.99 ± 1.20	12.61 ± 1.00
7s		10.51 ± 0.30	15.50 ± 0.13	19.04 ± 0.27
7t		9.75 ± 0.50	8.98 ± 1.10	9.79 ± 0.91
7u		9.92 ± 1.20	6.99 ± 0.50	6.78 ± 0.78
7v		10.94 ± 1.50	4.56 ± 0.57	5.97 ± 0.67
7w		14.51 ± 0.17	13.15 ± 0.23	24.75 ± 0.31
7x		6.25 ± 0.47	6.38 ± 0.50	4.99 ± 0.45
7y		13.58 ± 0.30	10.47 ± 0.09	7.59 ± 0.09
DDP		3.50 ± 0.10	6.10 ± 0.09	4.90 ± 0.05

^a Each compound was tested in triplicate. All error bars represent mean ± SD from three independent experiments.












group, which had a small ring at the *N'*-urea position, had a greater effect on the compound's anti-proliferative activity. We found that compounds **7k–7w**, which contained the aryl groups at the *N'*-urea position, generally had good anti-proliferative properties. The impact of the substituent at the phenyl ring was investigated by introducing halogen (F, Br, or I), methyl (CH₃), trifluoromethyl (CF₃), and/or methoxy (OCH₃) groups. The results revealed that *p*-substitution at the phenyl ring might not be helpful for their anti-proliferative properties. Compound **7k** had lower IC₅₀ values than **7l** or **7o**. Compound **7t** had lower IC₅₀ values than **7q**. Compounds with Br (**7r** or **7u**) and I (**7v**) at the C-4 position of phenyl ring exhibited better inhibition

against tested human cancer cell lines when compared with **7q** or **7s**, where F was introduced at the C-4 position of phenyl ring, as shown in Table 1. The remaining derivatives showed moderate activity. The presence of aromatic heterocyclic, such as pyridyl (**7x**) and pyrimidine (**7y**), at the urea end enhanced the anti-proliferative activity.

2.2.2. 1-(2-(Adamantan-1-yl)-1H-indol-5-yl)-3-substituted thiourea derivatives. We generated an additional series of thiourea derivatives with the functional group adamant (Ad) at the C2-position of the indole ring. This allowed us to explore the effect of the urea group on the cancer cells' proliferation. These thiourea derivatives were generally less active against H460,



Table 2 Anti-proliferative activity (IC₅₀, μM) of thiourea derivatives 9a–9o^a

Compound	R	IC ₅₀ (μM) ± S.D.		
		H460	HepG2	MCF-7
9a		20.23 ± 0.12	15.93 ± 0.17	25.89 ± 0.20
9b		27.25 ± 1.40	18.02 ± 1.00	21.13 ± 0.98
9c		>100	>100	>100
9d		>100	>100	>100
9e		30.20 ± 0.88	35.50 ± 0.85	25.00 ± 0.20
9f		14.52 ± 0.10	22.20 ± 0.18	16.96 ± 0.17
9g		25.36 ± 0.15	26.12 ± 0.10	19.62 ± 0.10
9h		22.23 ± 0.18	22.36 ± 0.15	26.36 ± 0.19
9i		38.54 ± 0.18	32.56 ± 0.25	28.11 ± 0.52
9j		31.80 ± 0.85	22.10 ± 1.00	26.01 ± 1.00
9k		25.19 ± 0.95	29.06 ± 1.10	18.07 ± 0.85
9l		21.80 ± 1.55	15.74 ± 0.65	20.47 ± 1.89
9m		25.80 ± 1.55	28.48 ± 1.45	23.80 ± 0.65
9n		41.89 ± 1.20	22.20 ± 1.40	28.1 ± 2.10
9o		20.13 ± 1.40	17.22 ± 1.30	21.60 ± 0.60
DDP		3.50 ± 0.10	6.10 ± 0.09	4.90 ± 0.05

^a Each compound was tested in triplicate. All error bars represent mean ± SD from three independent experiments.



HepG2 and MCF-7 cells than the urea derivatives (Table 2). Among the thiourea derivatives, compound **9f** had the highest anti-proliferative activity against H460 cells ($14.52 \pm 0.10 \mu\text{M}$) and MCF-7 cells ($16.96 \pm 0.17 \mu\text{M}$). Compound **9a** had the highest cellular anti-proliferative activity against HepG2 cells ($15.93 \pm 0.17 \mu\text{M}$). Both displayed lower growth inhibition

activity for the cancer cells when compared to compounds **7f** and **7a** in the urea series. The follow-up studies focused on urea derivatives.

2.3. *In vitro* cytotoxicity of urea derivatives against two normal cell lines

Twelve urea derivatives that showed prominent activity within all three of the human cancer cell lines with IC_{50} values down to $20 \mu\text{M}$ were assessed within the *in vitro* cytotoxic activity against the human normal lung MCR-5 cell line and the normal hepatocytes LO2 cell line. These urea derivatives' IC_{50} values for the MCR-5 cells were above $45.0 \mu\text{M}$. They exhibited good anti-proliferative activity against the LO2 cells with IC_{50} values (after 48 h of treatment) ranging from $4.0 \mu\text{M}$ to $35.0 \mu\text{M}$, as shown in Table 3. This demonstrated these compounds were less toxic for the MCR-5 cells than for the LO2 cells. The IC_{50} ratio of the normal cells to the cancer cells was termed the "relative toxicity index" (RTI). The RTI was estimated to investigate their sensitivity between the normal and the tumour cells in the two human tissue systems (lung and liver). In the lung system, the tested urea derivatives were sensitivity to cancer H460 cells, with RTI values up to 4.70. Most of the urea derivatives in the liver system showed lower selective between the human liver cancer HepG2 cells and the normal hepatocytes LO2 cell line ($\text{RTI} < 2$). This excluded compounds **7f**, **7t** and **7v**. The results indicated that the normal lung MCR-5 cells were more resistant to the toxic activity of these compounds than the lung cancer H460 cells. A majority of the compounds did not

Table 3 *In vitro* cytotoxicity of urea derivatives on normal cells^a

Compound	MRC-5		LO2	
	IC_{50} (μM) \pm S.D.	RTI ^b	IC_{50} (μM) \pm S.D.	RTI ^c
7a	77.37 ± 0.07	13.41	5.43 ± 0.09	0.92
7f	>100	>200	5.52 ± 0.04	19.71
7j	68.25 ± 0.11	5.80	33.32 ± 0.09	1.51
7k	56.35 ± 0.08	4.70	7.71 ± 0.07	0.59
7n	85.76 ± 0.13	6.65	13.95 ± 0.14	0.63
7s	73.86 ± 0.11	7.03	3.44 ± 0.10	0.22
7t	>100	>10.26	29.64 ± 0.13	3.30
7u	50.34 ± 0.12	5.07	5.12 ± 0.09	0.73
7v	63.71 ± 0.06	5.82	14.73 ± 0.07	3.23
7w	>100	>6.89	5.19 ± 0.06	0.39
7x	46.38 ± 0.09	7.42	4.46 ± 0.05	0.71
7y	67.35 ± 0.12	5.96	7.64 ± 0.05	0.73
DDP	>100	>28.57	39.69 ± 0.16	6.51

^a Each compound was tested in triplicate. All error bars represent mean \pm SD from three independent experiments. ^b The IC_{50} ratio is between lung normal MRC-5 cells to cancer H460 cells. ^c The IC_{50} ratio is between liver normal LO2 cells to cancer HepG2 cells.




Fig. 1 The Nur77 activation of compounds **7n**, **7w**, and **7s** in H460 cells and their apoptosis induction in H460, HepG2, MCF-7 and NIH-3T3. (A) Time-course analysis. H460 cancer cells treated with compounds ($10 \mu\text{M}$) for 0.5 h, 1 h, 3 h, 5 h, and 7 h were analysed to detect Nur77 levels via western blotting. (B) Dose dependent effect of compounds to activate Nur77. H460 cancer cells treated with compounds ($5 \mu\text{M}$, $10 \mu\text{M}$, and $15 \mu\text{M}$) for 3 h were analysed via western blotting. (C) The apoptotic effects of compounds **7n**, **7s**, and **7w** in H460, HepG2 and MCF-7 cancer cells. These three cancer cell lines were initially treated with $10 \mu\text{M}$ compounds for 24 h and then analysed for the cleavage of Parp protein via western blotting. (D) The apoptotic effects of compounds in NIH-3T3 cells.



possess a selective resistance against the HepG2 cancer cells or the LO2 normal hepatocytes cells.

2.4. The Nur77 activation ability of compounds with IC₅₀ values below 20 μM in H460

A popular research model has showed that H460 cancer cells are sensitive to the Nur77 dependent apoptotic effect.^{10,40} Our synthesized urea derivatives had a good sensitivity between the normal MCR-5 cells and the tumour H460 cells that were isolated from human lung tissue. So, we investigated whether our synthesized urea derivatives with IC₅₀ values below 20 μM could activate Nur77 in the H460 cancer cells. There were three compounds (**7n**, **7s**, and **7w**) that activated Nur77. Results showed that Nur77 was activated upon treatment with 10 μM of the compounds (**7n**, **7s**, and **7w**) in a time-dependent manner (Fig. 1(A)). Nur77 activation was observed in H460 cells treated with **7n/7s** for 0.5 h. This activation was delayed for 1 h in compound **7w**. Nur77 was activated further when treated for 3 h and 5 h with any of the compounds. The activation was maintained at a high level at 7 h. We examined whether Nur77 activation was also dose-dependent. H460 cancer cells were treated with various concentrations of each compound for 3 h (5 μM, 10 μM, and 15 μM) (Fig. 1(B)). As the concentration of each compound increased, the activation of Nur77 improved. Note, when equal amounts of protein lysates (40 μg) was added, **7s** was more effective in up regulating Nur77 than **7n** and **7w**. **7w** was the weakest compound.

2.5. The apoptosis induction of **7n**, **7w** and **7s** in H460, HepG2, MCF-7, and NIH-3T3

Apoptosis is a popular approach used by a majority of the anticancer drugs to kill tumour cells.³⁸ Apoptosis stimulation is considered standard and is the best strategy for anticancer therapy.³⁹ Compounds **7n**, **7s**, and **7w** were selected to study the apoptotic effects in various human cancer cells. These cancer cell lines were treated with the three compounds at 10 μM for 24 h to induce apoptosis. The cleavage of PARP protein was used as a sensitive apoptotic marker that occurred early in the apoptotic response. It was then examined by western blotting. The PARP cleavage was observed in various degrees in the tested cell lines (Fig. 1(C)). The induction of PARP cleavage of all three compounds was apparent in H460 cancer cells. Compounds **7n** and **7s** had better activity than **7w**. Compounds **7n** and **7s** induced the cleavage of PARP protein in HepG2 cancer cells, but **7w** did not have an effect. Compound **7s** was the only compound that slightly induced PARP cleavage in MCF-7 cancer cells. These results suggested that **7n**, **7s**, and **7w** were more potent inducers of apoptosis in H460 cancer cell line than the other two cell lines. Compound **7s** showed higher apoptosis against these three human cancer cell lines than compounds **7w** and **7n**. The apoptotic effect of these compounds at various concentrations was tested in NIH-3T3 mouse embryo cells over 24 h. The results showed that all of the three compounds did not induce PARP cleavage at various concentrations for 24 h (Fig. 1(D)). This indicated that these three compounds had little effect on normal cells.

2.6. Compound **7s** induced apoptosis depending the Nur77 activation and the best growth inhibition of H460 cancer cells

We used RNA interference technology to confirm that the apoptosis effect of these compounds was related with the activation of Nur77. The H460 cancer cells were transfected with shNur77 or shctr for 24 h and then treated with 10 μM of the compounds for an additional 24 h. The cleavage of PARP and the expression of Nur77 were examined (Fig. 2(A)). The compounds still induced Parp cleavage in cells transfected with the shctr. In cells transfected with the shNur77, the Nur77 was effectively blocked. The degree of PARP cleavage of **7s** and **7n** was significantly down regulated, particularly in **7s**. There was little change for **7w**. This suggested that Nur77 could play a key role in the apoptosis effect of **7s** in H460 cells.

The cell growth inhibition of **7n**, **7s**, and **7w** in H460 cancer cells was confirmed with MTT assays. The effects of these compounds on the growth of H460 cells at various concentrations (5 μM, 10 μM, and 15 μM) were tested at 24 h, 48 h, 72 h, and 96 h (Fig. 2(B)). The results showed that these compounds inhibited the proliferation of the H460 cell line in a dose- and time-dependent manner. Compound **7s** demonstrated superior growth inhibition on H460 cells. At exposure times up to 96 h,




Fig. 2 The compounds induced apoptosis and inhibited growth of H460 cells. (A) Nur77 expression was required for the apoptotic effect of **7n**, **7s**, and **7w** in H460 cells. H460 cancer cells were transfected with control or Nur77 shRNA for 24 h, then treated with or without 10 μM of the compounds for an additional 24 h. The Parp cleavage and Nur77 expression were analysed via western blotting. (B) Growth inhibition activities of compounds on H460 cells were assessed with MTT assay. H460 cancer cells treated with these three compounds at various concentrations (5 μM, 10 μM and 15 μM) and tested at 24 h, 48 h, 72 h, and 96 h time points. DMSO was used as the negative control.



the inhibition rates of **7n** at the various concentrations (5 μM , 10 μM and 15 μM) were 35.02%, 70.73%, and 86.50%. The inhibition rates for **7w** were 18.02%, 34.47%, and 51.71%. The inhibition rates for **7s** were 75.70%, 95.72%, and 96.05%. The anti-proliferation abilities of these three compounds were similar to their apoptosis induction and Nur77 activation effects in H460 cells.




Fig. 3 Molecular docking 3D and 2D models of **7s** and Nur77. (A) The interactions between Nur77 are displayed on the grey surface presentation. The **7s** is represented in the yellow stick. The protein surface conformation is the crystal structure of homodimer of the orphan nuclear receptor Nur77 (PDB ID: 4RE8). The moiety of difluorobenzene of ligand inserted deeply into the hydrophobic pocket. (B) Close-up view depiction of the superposition of Nur77 LBP bound to **7s**. The Nur77 binding site is presented with a coloured ribbon. Neighbouring amino acids were displayed in lines within a distance of 5 Å approximately to **7s** (the hydrogen bond between **7s** and LEU 175 are shown as yellow dots). (C) 2D binding model of **7s** with Nur77: hydrogen bonds are indicated with solid arrows, colour lines around **7s** stand for the binding pocket and the residues in colours nearby established the pocket. The green colour denotes the hydrophobic nature of amino acids, the red colour denotes the acid amino acids, the purple denotes the alkalinity of amino acids, the cyan denotes the polar amino acids, and the grey points of ligand atoms denotes the solvent accessibility.

2.7. Molecular docking study of **7s** and Nur77

The *in vitro* bioassay revealed the high ability of compound **7s** when activating Nur77 in H460 cancer cells. We performed a molecular docking study for **7s** and Nur77. The docking study revealed that compound **7s** exhibited a promising binding affinity with Nur77 with a docking binding energy of $-7.30 \text{ kcal mol}^{-1}$. The specific non-bonded interactions between **7s** and the residues of Nur77 in 3D and 2D are shown in Fig. 3. The urea group of compound **7s** formed a hydrogen bonding interaction with the backbone's carbonyl group of amino acid LEU175. The moiety of difluorobenzene inserted deeply into the hydrophobic pocket formed by PHE172, LEU224, VAL167, PHE158, LEU162 and LEU118. The adamantane group extended out of the pocket and interacted with the surface of ALA201, ASN198, and GLN197 *via* hydrophobic interactions. The hydrogen bond between **7s** and Nur77 could still exist even though the LEU175 mutated to other amino acids (like an alanine). This indicated that the hydrogen bond between **7s** and the backbone of LEU175 could be important for the affinity and selection of the complex **7s**-Nur77.

3. Conclusion

In this study, we synthesized and conducted a biological evaluation of two new series of 1-(2-(adamantan-1-yl)-1*H*-indol-5-yl)-3-substituted urea/thiourea derivatives as potential anticancer agents. The synthetic method was relatively simple. The target compounds were easily purified and produced in high yields. Among of synthesized compounds, most showed moderate anti-proliferative activity against all three of the tested cancer cell lines. The compounds with prominent anticancer activity also exhibited good sensitivity between the normal (MRC-5) and the tumour (H460) cell lines that were isolated from lung tissue. Three compounds that could active Nur77 were obtained: **7n**, **7s**, and **7w**. They were evaluated for their abilities to induce apoptosis in various cells and the inhibition of cell growth in H460 cancer cells. The results showed that **7n** and **7s** achieved better anticancer activity than **7w**. The shRNA experiment revealed that the apoptosis effect of **7n** and **7s** was dependent on Nur77, particularly in **7s**. Compound **7w** could have an alternative mechanism. The molecular docking suggested that compound **7s** exhibited a promising binding affinity with Nur77. These results are helpful in the development of a Nur77 targeted drug. Further studies are also required to determine their roles in preventing cancer.

4. Experimental section

4.1. Chemistry

All reagents were commercially available and used without further purification, unless otherwise indicated. Reactions were magnetically stirred and monitored by thin-layer chromatography (TLC) on Merck silica gel 60F-254 by fluorescence. The target compounds were purified by column chromatography. The purities of the target compounds were assessed by high performance liquid chromatography (HPLC) with a COSMOSIL



C18-MS-II column (250 mm × 4.6 mm i.d., 5 μm). The HPLC analysis was performed on an Agilent Technologies 1100 Series HPLC system. The mobile phase was acetonitrile (A) and water (B), eluted as the following gradient program: A from 80% to 100% and B from 20% to 0% during 0–20 min. The flow rate was 1 mL min⁻¹ and the detection wavelengths were 254 nm and 280 nm. ¹H-NMR and ¹³C-NMR spectra were obtained using a Bruker AV2 600 Ultra shield spectrometer at 600 and 150 MHz respectively. Chemical shifts were given in parts per million (ppm) relative to tetramethyl-silane (TMS) as an internal standard. Multiplicities were abbreviated as follows: single (s), doublet (d), doublet–doublet (dd), doublet–triplet (dt), triplet (t), triplet–triplet (tt), triplet–doublet (td), quartet (q), quartet–doublet (qd), multiplet (m), and broad signal (br s). High-resolution mass spectral (HRMS) data were acquired on a Q Exactive. Melting points were measured on a SGWX-4 micro-melting point spectrometer and were uncorrected.

4.1.1. *N*-*o*-Tolylcycloadamantanecarboxamide (2). A mixture of 10.0 mmol of *o*-toluidine, 10.0 mmol of 1-adamantanecarbonyl chloride, and 7.0 mmol of anhydrous potassium carbonate in 50 mL of toluene was stirred at room temperature for 4 h. The resulting solid was first filtered off and stirred at room temperature for 1.5 h with 50 mL of H₂O. The solid was filtered off and recrystallized from the appropriate solvent. White solid (75.5%). ¹H NMR (600 MHz, CDCl₃): δ 7.88 (d, *J* = 8.1 Hz, 1H, Ar-H), 7.18–7.24 (m, 2H, C=ONH and Ar-H), 7.17 (d, *J* = 7.5 Hz, 1H, Ar-H), 7.05 (dt, *J* = 1.1, 7.4 Hz, 1H, Ar-H), 2.26 (s, 3H, Ar-CH₃), 1.99–2.13 (m, 3H, Ad-H), 1.97–2.01 (m, 6H, Ad-H), 1.73–1.80 (m, 6H, Ad-H); ESI-HRMS (+): *m/z* [M + H]⁺ calculated for C₁₈H₂₄NO⁺, 270.1852, found 270.1853; [M + Na]⁺ calculated for C₁₈H₂₃NONa⁺, 292.1672, found 292.1669.

4.1.2. 2-Adamantane-1*H*-indole (3). A stirred solution of 10 mmol of *N*-*o*-tolylcycloadamantanecarboxamide (2) in 50 mL of THF under a N₂ atmosphere was maintained at an internal temperature of –5 to 5 °C and treated dropwise with 0.1–0.15 mol of *n*-BuLi as 2.5 M *n*-BuLi in hexane. The stirred mixture was kept at ambient temperature, cooled in an ice bath, and treated dropwise with 12 mL of 2 M HCl. The organic layer was separated and the aqueous layer washed with C₆H₆. The combined organic layer was dried with anhydrous MgSO₄, filtered, and concentrated *in vacuo*. Recrystallization of the residue was from the appropriate solvent. White solid (56.5%). ¹H NMR (600 MHz, CDCl₃): δ 7.30 (d, *J* = 7.9 Hz, 1H, Ar-H), 7.18 (dd, *J* = 0.6, 8.1 Hz, 1H, Ar-H), 6.88 (dt, *J* = 1.1, 7.5 Hz, 1H, Ar-H), 6.77–6.83 (m, 1H, Ar-H), 5.98 (d, *J* = 0.6 Hz, 1H, H-3'), 1.96–2.00 (m, 3H, Ad-H), 1.91–1.94 (m, 6H, Ad-H), 1.70–1.78 (m, 6H, Ad-H); ESI-HRMS (+): *m/z* [M + H]⁺ calculated for C₁₈H₂₂N⁺, 252.1747, found 252.1748; [M + Na]⁺ calculated for C₁₈H₂₁NNa⁺, 274.1566, found 274.1568.

4.1.3. 2-Adamantane-5-nitro-1*H*-indole (4). In a 250 mL round-bottom flask, 2.51 g of 2-adamantane-1*H*-indole (10 mmol) was dissolved in 10 mL of H₂SO₄ after vigorous stirring. In a separate flask, 0.94 g of NaNO₃ (1.1 × 10 mmol) was dissolved in 10 mL of H₂SO₄, also after vigorous stirring, and then was added dropwise (*via* addition funnel) to the above mixture. After addition, the reaction mixture was stirred for another 10 min and then poured into 200 mL of ice water, precipitating

a yellow product. The product was isolated *via* filtration and washed with cold water. After 12 h of drying under vacuum, 2.89 g of yellow product was isolated (97%). ¹H NMR (600 MHz, DMSO-*d*₆): δ 11.65 (br s, 1H, NH), 8.44 (d, *J* = 2.2 Hz, 1H, Ar-H), 7.93 (dd, *J* = 2.2, 9.0 Hz, 1H, Ar-H), 7.44 (d, *J* = 8.8 Hz, 1H, Ar-H), 6.38 (d, *J* = 1.5 Hz, 1H, H-3'), 2.04–2.08 (m, 3H, Ad-H), 1.96–1.99 (m, 6H, Ad-H), 1.72–1.80 (m, 6H, Ad-H); ¹³C NMR (150 MHz, DMSO-*d*₆): δ 154.0 (C-2'), 140.8 (C-NO₂), 139.9 (Ar-CH), 127.7 (Ar-C), 116.9 (Ar-C), 116.3 (Ar-CH), 111.4 (Ar-CH), 98.2 (C-3'), 41.9 (Ad-C), 36.6 (s, 3C, Ad-C), 34.1 (s, 3C, Ad-C), 28.2 (s, 3C, Ad-C); ESI-HRMS (+): *m/z* [M + H]⁺ calculated for C₁₈H₂₁N₂O₂⁺, 297.1598, found 297.1599; [M + Na]⁺ calculated for C₁₈H₂₀N₂O₂Na⁺, 319.1417, found 319.1417.

4.1.4. 2-Adamantane-1*H*-indol-5-amine (5). Compound 4 (2.96 g, 10 mmol) was dissolved in 150 mL of ethanol. 10% Pd/C was added (300 mg), and the mixture was subjected to H₂ (38 psi) using a Parr hydrogenator for 3.5 h. The mixture was filtered over Celite, which was washed with methanol. After concentration and drying under vacuum, 2.5 g of a brown powder (94%) was isolated. ¹H NMR (600 MHz, CDCl₃): δ 7.80 (s, 1H, NH), 7.10 (d, *J* = 8.4 Hz, 1H, Ar-H), 6.86 (d, *J* = 2.2 Hz, 1H, Ar-H), 6.57 (dd, *J* = 2.2, 8.4 Hz, 1H, Ar-H), 6.05 (dd, *J* = 2.2 Hz, 1H, H-3'), 3.45 (br s, 2H, NH₂), 2.06–2.12 (m, 3H, Ad-H), 1.94–1.98 (m, 6H, Ad-H), 1.75–1.81 (m, 6H, Ad-H); ¹³C NMR (150 MHz, CDCl₃): δ 149.9 (C-2'), 139.3 (C-NH₂), 130.3 (Ar-C), 129.4 (Ar-C), 111.6 (Ar-CH), 110.8 (Ar-CH), 105.3 (Ar-CH), 95.5 (C-3'), 42.6 (Ad-C), 36.8 (s, 3C, Ad-C), 33.7 (s, 3C, Ad-C), 28.5 (s, 3C, Ad-C); ESI-HRMS (+): *m/z* [M + H]⁺ calculated for C₁₈H₂₃N₂⁺, 267.1856, found 267.1858.

4.1.5. 5-Isocyanato-1*H*-indole-adamantane (6). To a solution of ethyl 5-amino-1*H*-indole-2-adamantane 2.66 g (10.0 mmol) dissolved in THF (80 mL) was slowly dropped into a stirred solution of triphosgene 2.98 g, (10.0 mmol) in THF (10 mL) by using a constant-pressure dropping funnel. NEt₃ (3 mL, 21.0 mmol) was then added slowly to the reaction mixture after the ethyl 5-amino-1*H*-indole-2-adamantane was added. The reaction mixture was stirred at 0 °C for 2 h. After completion of the reaction, the mixture was concentrated and purified by column chromatography using appropriate mixtures of EtOAc and PE to yield the titled compound. White solid (61.5%). ¹H NMR (600 MHz, CDCl₃): δ 8.01 (s, 1H, NH), 7.21 (d, *J* = 8.4 Hz, 1H, Ar-H), 6.85 (dd, *J* = 2.0, 8.4 Hz, 1H, Ar-H), 6.17 (d, *J* = 1.5 Hz, 1H, H-3'), 2.07–2.15 (m, 3H, Ad-H), 1.95–2.00 (m, 6H, Ad-H), 1.74–1.85 (m, 6H, Ad-H); ¹³C NMR (150 MHz, CDCl₃): δ 151.0 (C-2'), 133.2 (Ar-C), 129.0 (Ar-C), 125.1 (Ar-C), 123.6 (N=C=O), 118.1 (Ar-CH), 115.5 (Ar-CH), 111.1 (Ar-CH), 96.4 (C-3'), 42.5 (Ad-C), 36.7 (s, 3C, Ad-C), 33.8 (s, 3C, Ad-C), 28.4 (s, 3C, Ad-C).

4.1.6. General method for the synthesis of compounds 7a–7y. To a solution of 5-isocyanato-1*H*-indole-adamantine 6 (0.12 g, 0.4 mmol) in toluene (5 mL) aliphatic, aromatic or heteroaromatic amine (0.4 mmol) was added, and the reaction mixture was heated at 60 °C for 4 h. After completion of the reaction, the mixture was concentrated and purified by column chromatography using appropriate mixtures of CH₂Cl₂ and MeOH.

4.1.6.1 Compound 7n. White solid; yield: 87.3%; HPLC purity: 95.5% (*t*_R = 21.05 min); mp: 265–267 °C; ¹H NMR (600



MHz, DMSO- d_6): δ 10.74 (s, 1H, NH-1'), 8.90 (s, 1H, C=ONH-1), 8.46 (s, 1H, C=ONH-3), 8.04 (s, 1H, H-2'), 7.56 (d, $J = 1.5$ Hz, 1H, H-4'), 7.54–7.56 (m, 1H, Ar-H), 7.46–7.51 (m, 1H, Ar-H), 7.27 (d, $J = 7.7$ Hz, 1H, Ar-H), 7.21 (d, $J = 8.4$ Hz, 1H, H-7'), 7.01 (dd, $J = 2.0, 8.4$ Hz, 1H, H-6'), 6.03 (d, $J = 1.7$ Hz, 1H, H-3'), 2.03–2.08 (m, 3H, Ad-H), 1.92–1.99 (m, 6H, Ad-H), 1.72–1.80 (m, Ad-H); ^{13}C NMR (150 MHz, DMSO- d_6): δ 153.4 (C=O), 150.8 (C-2'), 141.5 (C-1''), 133.0 (C-8'), 131.1 (C-5'), 130.3 (C-5''), 129.96 (q, $J = 30.8$ Hz, CF $_3$ C), 128.4 (C-9'), 124.8 (q, $J = 271.8$ Hz, CF $_3$), 122.0 (C-6''), 118.0 (q, $J = 4.4$ Hz, C-2''), 114.35 (C-6'), 114.30 (q, $J = 4.4$ Hz, C-4''), 111.1 (C-7'), 110.5 (C-4'), 95.4 (C-3'), 42.3 (Ad-C), 36.8 (s, 3C, Ad-C), 33.9 (s, 3C, Ad-C), 28.4 (s, 3C, Ad-C); ESI-HRMS (+): m/z [M + H] $^+$ calculated for C $_{26}$ H $_{27}$ F $_3$ N $_3$ O $^+$, 454.2101, found 454.2101; [M + Na] $^+$ calculated for C $_{26}$ H $_{26}$ F $_3$ N $_3$ ONa $^+$, 476.192, found 476.1922.

4.1.6.2 Compound 7s. White solid; yield: 89.6%; HPLC purity: 96.4% ($t_R = 17.89$ min); mp: 178–181 °C; ^1H NMR (600 MHz, DMSO- d_6): δ 10.73 (d, $J = 1.3$ Hz, 1H, NH-1'), 8.72 (s, 1H, C=ONH-1), 8.36 (d, $J = 2.0$ Hz, 1H, C=ONH-3), 8.12–8.17 (m, 1H, 6''), 7.56 (d, $J = 1.8$ Hz, 1H, H-4'), 7.26–7.30 (m, 1H, 5''), 7.20 (d, $J = 8.4$ Hz, 1H, 7'), 7.01–7.05 (m, 1H, H-3''), 6.99 (dd, $J = 2.1, 8.5$ Hz, 1H, H-6'), 6.02 (d, $J = 1.7$ Hz, 1H, H-3'), 2.03–2.08 (m, 3H, Ad-H), 1.93–1.98 (m, 6H, Ad-H), 1.72–1.80 (m, 6H, Ad-H); ^{13}C NMR (150 MHz, DMSO- d_6): δ 156.8 (dd, $J = 12.1, 241.0$ Hz, CF-2''), 153.1 (C=O), 152.3 (dd, $J = 12.1, 241.5$ Hz, CF-4''), 150.8 (C-2'), 132.9 (C-8'), 131.2 (C-5'), 128.4 (C-9'), 125.1 (dd, $J = 3.3, 11.0$ Hz, C-1''), 121.9 (dd, $J = 3.3, 8.8$ Hz, C-6''), 113.9 (C-6'), 111.4 (dd, $J = 23.1, 24.2$ Hz, C-5''), 111.1 (C-7'), 110.0 (C-4'), 104.1 (dd, $J = 3.3, 21.3$ Hz, C-3''), 95.4 (C-3'), 42.3 (Ad-C), 36.8 (s, 3C, Ad-C), 33.9 (s, 3C, Ad-C), 28.4 (s, 3C, Ad-C); ESI-HRMS (+): m/z [M + H] $^+$ calculated for C $_{25}$ H $_{26}$ F $_2$ N $_3$ O $^+$ 422.2038, found 422.2030; [M + Na] $^+$ calculated for C $_{25}$ H $_{25}$ F $_2$ N $_3$ ONa $^+$, 444.1850, found 444.1852. (ESI Fig. S1†)

4.1.6.3 Compound 7w. White solid; yield: 85.8%; HPLC purity: 94.8% ($t_R = 20.80$ min); mp: 271–273 °C; ^1H NMR (600 MHz, DMSO- d_6): δ 10.74 (s, 1H, NH-1'), 8.76 (s, 1H, C=ONH-1), 8.55 (s, 1H, C=ONH-3), 7.88–7.98 (m, 1H, H-6''), 7.56 (d, $J = 1.7$ Hz, 1H, H-4'), 7.23–7.27 (m, 1H, H-5''), 7.21 (d, $J = 8.6$ Hz, 1H, 7') 6.99 (dd, $J = 2.0, 8.6$ Hz, 1H, H-6'), 6.03 (d, $J = 1.7$ Hz, 1H, H-3'), 2.03–2.08 (m, 3H, Ad-H), 1.93–1.98 (m, 6H, Ad-H), 1.72–1.80 (m, 6H, Ad-H); ^{13}C NMR (150 MHz, DMSO- d_6): δ 152.9 (C=O), 150.8 (C-2'), 145.3 (ddd, $J = 2.2, 9.9, 242.1$ Hz, CF-2''), 141.7 (ddd, $J = 3.3, 11.0, 245.4$ Hz, CF-4''), 139.5 (dt, $J = 14.3, 246.5$ Hz, CF-3''), 126.5 (dd, $J = 3.3, 7.7$ Hz, C-6''), 133.0 (C-8'), 131.0 (C-5'), 128.4 (C-9'), 115.2 (m, C-1''), 114.0 (C-6'), 112.1 (dd, $J = 3.3, 17.1$ Hz, C-5''), 111.1 (C-7'), 110.1 (C-4'), 95.4 (C-3'), 42.3 (Ad-C), 36.8 (s, 3C, Ad-C), 33.9 (s, 3C, Ad-C), 28.4 (s, 3C, Ad-C); ESI-HRMS (+): m/z [M + H] $^+$ calculated for C $_{25}$ H $_{25}$ F $_3$ N $_3$ O $^+$, 440.1944, found 440.1938; [M + Na] $^+$ calculated for C $_{25}$ H $_{24}$ F $_3$ N $_3$ ONa $^+$, 462.1764, found 462.1760.

At the series of urea derivatives, the other target compounds were synthesized following the general procedure as described above with the yield of 84–90%. Their structures were confirmed by the spectroscopic data including ^1H NMR, ^{13}C NMR, and ESI-HRMS (see 'ESI†').

4.1.7. 5-Isocyanato-1H-indole-adamantane (8). To a solution of ethyl 5-amino-1H-indole-2-adamantane (4.1 g, 15.5

mmol) and triethylenediamine (2.08 g, 18.6 mmol) in 40 mL of toluene, CS $_2$ (3.5 g, 46.5 mmol) was added slowly. The resulting mixture was stirred at room temperature for 8 h. After filtration, the filter cake was washed with toluene and dried. Obtained intermediate was suspended in 40 mL of DCM. Then, a 25 mL of DCM solution of BTC (5.0 g, 17.0 mmol) was added slowly under 0–5 °C. The mixture was stirred for 2 h at room temperature, and then was refluxed for 1.5–2 h. After filtration, the filtrate was concentrated *in vacuo*. The mixture was concentrated and purified by column chromatography using appropriate mixtures of EtOAc and PE to yield the titled compound. White solid (62.5%). ^1H NMR (600 MHz, CDCl $_3$): δ 8.12 (br s, 1H, NH), 7.40 (d, $J = 1.8$ Hz, 1H, H-4'), 7.23 (d, $J = 8.4$ Hz, 1H, H-7'), 6.98 (dd, $J = 2.0, 8.4$ Hz, 1H, H-6'), 6.20 (d, $J = 1.5$ Hz, 1H, H-3'), 2.08–2.14 (m, 3H, Ad-H), 1.94–1.99 (m, 6H, Ad-H), 1.74–1.85 (m, 6H, Ad-H); ^{13}C -NMR (150 MHz, CDCl $_3$): δ 151.4 (C-2'), 134.1 (C-8'), 131.8 (C-9'), 128.7 (C-5'), 122.6 (N=C=S), 119.0 (C-6'), 117.3 (C-7'), 111.2 (C-4'), 96.8 (C-3'), 42.5 (Ad-C), 36.7 (s, 3C, Ad-C), 33.9 (s, 3C, Ad-C), 28.4 (s, 3C, Ad-C).

4.1.8. General method for the synthesis of compounds 9a–9o. To a solution of 5-isocyanato-1H-indole-adamantane (8) (0.12 g, 0.4 mmol) in toluene (5 mL), aliphatic, aromatic, or heteroaromatic amine (0.4 mmol) was added, and the reaction mixture was heated at 60 °C for 4 h. After completion of the reaction, the mixture was concentrated and purified by column chromatography using appropriate mixtures of CH $_2$ Cl $_2$ and MeOH.

4.1.8.1 Compound 9a. White solid; yield: 84.6%; mp: 285–287 °C; HPLC purity: 97.3% ($t_R = 21.07$ min); ^1H NMR (600 MHz, DMSO- d_6): δ 10.89 (s, 1H, NH-1'), 9.15 (s, 1H, C=SNH-1), 7.32 (d, $J = 1.7$ Hz, 1H, H-4'), 7.25 (d, $J = 8.4$ Hz, 1H, H-7'), 6.87 (dd, $J = 1.9, 8.5$ Hz, 1H, H-6'), 6.73 (br s, 1H, C=SNH-3), 6.07 (d, $J = 1.5$ Hz, 1H, H-3'), 2.03–2.09 (m, 3H, Ad-H), 1.93–1.98 (m, 6H, Ad-H), 1.72–1.80 (m, 6H, Ad-H), 1.45 (s, 9H, (CH $_3$) $_3$ C); ^{13}C NMR (150 MHz, DMSO- d_6): δ 180.3 (C=S), 151.1 (C-2'), 134.3 (C-8'), 130.2 (C-5'), 128.4 (C-9'), 118.9 (C-6'), 116.5 (C-7'), 111.3 (C-4'), 95.7 (C-3'), 53.0 ((CH $_3$) $_3$ C), 42.2 (Ad-C), 36.8 (s, 3C, Ad-C), 33.9 (s, 3C, Ad-C), 29.2 (s, 3C, (CH $_3$) $_3$ C), 28.4 (s, 3C, Ad-C); ESI-HRMS (+): m/z [M + H] $^+$ calculated for C $_{23}$ H $_{32}$ N $_3$ S $^+$, 382.2311, found 382.2307; [M + Na] $^+$ calculated for C $_{23}$ H $_{31}$ N $_3$ SNa $^+$, 404.2131, found 404.2126.

At the series of thiourea derivatives, the other final compounds were synthesized following the general procedure as described above with the yield of 84–92%. Their structures were characterized by NMR, ESI-HRMS and HPLC analyses. (see 'ESI†').

4.2. Biology materials and methods

4.2.1. Reagents and antibodies. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) and DMSO were purchased from Sigma-Aldrich. TurboFect Transfection Reagent, goat anti-rabbit and anti-mouse secondary antibody conjugated to horseradish peroxidase were from Thermo Fisher Scientific. Anti-Nur77 (3960S), anti-poly (ADP ribose) polymerase (Parp) (9542) and anti- β -actin (4970) were from Cell Signal Technology. Enhanced chemiluminescence reagents



from GE Healthcare and a cocktail of proteinase inhibitors from Roche were used in this study. All other chemicals used were commercial products of analytic grade obtained from Sigma.

4.2.2. Cell culture. All of the human cancer cell lines were obtained from the American Type Culture Collection (ATCC). MCR-5 normal lung cells were cultured in minimum essential medium (MEM) supplemented with 10% fetal bovine serum and kept in a CO₂ incubator which consisted of a humidified atmosphere of 5% CO₂ at 37 °C with 90% humidity. NCI-H460 lung cancer cells and LO2 normal hepatocytes cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, at 37 °C under 5% CO₂/95% air. MCF-7 breast cancer cells, HepG2 liver cancer cells, and NIH-3T3 mouse embryo cells were grown in Dulbeccos Modified Eagles Medium (DMEM) supplemented with 10% fetal bovine serum in a humidified atmosphere containing 5% CO₂ at 37 °C.

4.2.3. MTT assays. Cells were cultured in 96-well plate with 100 µL medium and the total amount of cells in each well was about 1×10^4 . Concentration gradients (5–7 different concentrations) of each compound were then added to cells (three repeats), cisplatin (DDP) as the positive control and dimethyl sulfoxide (DMSO) as the negative control. After 48 h treatment, 10 µL MTT (5 mg mL⁻¹) was added to each wells staining for 4 hours in cell incubator. Then in each well, medium was discarded and 100 µL DMSO was used, after short time shaking, the light intensity was measured at a wavelength of 490 nm in Microplate Reader (Thermo). At last, the IC₅₀ values (concentrations required to inhibit 50% of cell growth) were calculated using GraphPad Prism 5 software and cell inhibition curves were conducted.

4.2.4. Western blotting. Equal amounts of cell lysates were electrophoresed on 10% SDS polyacrylamide gel electrophoresis and transferred to the polyvinylidene difluoride (PVDF) membranes (0.22 µM). The membranes were blocked with 5% nonfat milk in TBST buffer (50 mM Tris-HCl, pH7.4, 150 mM NaCl and 0.1% Tween 20) for 1 h at room temperature and incubated with various primary antibodies overnight at 4 °C. After three TBST washes, the membranes were incubated with HRP-conjugated anti-mouse or anti-rabbit antibody for 2 h at room temperature. The final immunoreactive products were detected with an enhanced chemiluminescence (ECL) system.

4.2.5. shRNA transfection. The shNur77 (5'-ACAGTC-CAGCCATGCTCCT-3') transfection was performed using TurboFect Transfection Reagent according to the manufacturer's instructions. As a negative control, a no specific scrambled shct was used. The cells were then treated with **7n**, **7s** and **7w** for 24 h respectively.

4.2.6. Statistical analysis. The data were expressed as mean ± SD. Each assay was repeated in triplicate in three independent experiments. Statistical significance of differences between groups was analysed by using Student's *t*-test or analysis of variance. *P* < 0.05 was considered significant.

4.3 Molecular docking

4.3.1. Ligand and protein preparation. The 3-D structure of **7s** was drawn using Gauss view 5.0 and was optimized with

Gaussian 09 package⁴⁰ at the B3LYP/6-31G (d) level to serve as the docking ligand. The X-ray crystal structure of the Nur77 was downloaded from the protein Data Bank (PDB ID: 4RE8). All of the water molecules and other subunits (GOL, 3 MJ) were then removed, missing side chains were filled and hydrogen atoms were added, using the Schrödinger 2016-1 software (LLC, New York, NY, USA, 2016). The resulting hydrogen-Nur77 was used as the target receptor for molecular docking.

4.3.2. The docking experiments. Molecular docking was carried out using the Glide programme (Small-Molecule Drug Discovery Suite 2016-1: Glide, version 6.6, Schrödinger, LLC, NY, 2016.) in the standard precision (SP) mode to investigate the mechanism of interaction between the compound **7s** and protein Nur77. The binding site of native ligand 3 MJ was chosen for docking site. Throughout the docking process, the protein Nur77 was held rigid; only the torsional bonds of **7s** were permitted to be free. Default values were used for all the parameters during docking. The docking results presented here were analysed by using PyMOL software⁴¹ and Maestro, version 10.1.⁴²

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No. 81773600, 81302652, 31471273, 41376172 and 31461163002), the Project of South Center for Marine Research (No. 14GY023NF23). This research was also financially supported by Fujian Science and Technology project (No. 2014N5012). We also thank the College of Pharmaceutical Sciences, Xiamen University and the Department of Chemistry, College of Chemistry and Chemical Engineering, Xiamen University for providing us with the Shrodinger 2015-1 software and Gaussian 09 software.

Notes and references

- 1 A. Chawla, J. J. Repa, R. M. Evans and D. J. Mangelsdorf, *Science*, 2001, **294**, 1866–1870.
- 2 Z. Xia, X. Cao, E. Rico-Bautista, J. Yu, L. Chen, J. Chen, A. Bobkov, D. A. Wolf, X.-K. Zhang and M. I. Dawson, *MedChemComm*, 2013, **4**, 332–339.
- 3 Q. Wu, S. Liu, X. F. Ye, Z. W. Huang and W. J. Su, *Carcinogenesis*, 2002, **23**, 1583–1592.
- 4 S. O. Lee, X. Li, S. Khan and S. Safe, *Expert Opin. Ther. Targets*, 2011, **15**, 195–206.
- 5 M. A. Maxwell and G. Muscat, *Nucl. Recept. Signaling*, 2006, **4**, e002.
- 6 H. M. Mohan, C. M. Aherne, A. C. Rogers, A. W. Baird, D. C. Winter and E. P. Murphy, *Clin. Cancer Res.*, 2012, **18**, 3223–3228.
- 7 U. Moll, N. Marchenko and X. Zhang, *Oncogene*, 2006, **25**, 4725–4743.



- 8 L. De Léséleuc and F. Denis, *Cell Death Differ.*, 2006, **13**, 293–300.
- 9 F. Weih, R. P. Ryseck, L. Chen and R. Bravo, *Proc. Natl. Acad. Sci. U. S. A.*, 1996, **93**, 5533–5538.
- 10 Y. Li, B. Lin, A. Agadir, R. Liu, M. I. Dawson, J. C. Reed, J. A. Fontana, F. Bost, P. D. Hobbs and Y. Zheng, *Mol. Cell. Biol.*, 1998, **18**, 4719–4731.
- 11 H. Uemura and C. Chang, *Endocrinology*, 1998, **139**, 2329–2334.
- 12 Y. Y. Zhan, J. P. He, H. Z. Chen, W. J. Wang and J. C. Cai, *Cancer Lett.*, 2013, **329**, 37–44.
- 13 S. O. Lee, T. Andey, U. H. Jin, K. Kim, M. Singh and S. Safe, *Oncogene*, 2012, **31**, 3265–3276.
- 14 H. Wu, Y. Lin, W. Li, Z. Sun, W. Gao, H. Zhang, L. Xie, F. Jiang, B. Qin and T. Yan, *FASEB J.*, 2011, **25**, 192–205.
- 15 S. To, W. Zeng, J. Zeng and A. Wong, *Br. J. Cancer*, 2014, **110**, 935–945.
- 16 S. O. Lee, M. Abdelrahim, K. Yoon, S. Chintharlapalli, S. Papineni, K. Kim, H. Wang and S. Safe, *Cancer Res.*, 2010, **70**, 6824–6836.
- 17 J. Liu, W. Zhou, S. S. Li, Z. Sun, B. Lin, Y. Y. Lang, J. Y. He, X. Cao, T. Yan and L. Wang, *Cancer Res.*, 2008, **68**, 8871–8880.
- 18 S. D. Cho, S. O. Lee, S. Chintharlapalli, M. Abdelrahim, S. Khan, K. Yoon, A. M. Kamat and S. Safe, *Mol. Pharmacol.*, 2010, **77**, 396–404.
- 19 T. Sibayama-Imazu, Y. Fujisawa, Y. Masuda, T. Aiuchi, S. Nakajo, H. Itabe and K. Nakaya, *J. Cancer Res. Clin. Oncol.*, 2008, **134**, 803–812.
- 20 K. Yoon, S. O. Lee, S. D. Cho, K. Kim, S. Khan and S. Safe, *Carcinogenesis*, 2011, **32**, 836–842.
- 21 H. Z. Chen, Q. F. Liu, L. Li, W. J. Wang, L. M. Yao, M. Yang, B. Liu, W. Chen, Y. Y. Zhan, M. Q. Zhang, J. C. Cai, Z. H. Zheng, S. C. Lin, B. A. Li and Q. Wu, *Gut*, 2012, **67**, 714–724.
- 22 S. Zhe, X. H. Cao, M. M. Jiang, Y. K. Qiu, H. Zhou, L. Q. Chen, B. Qin, H. Wu, F. Q. Jiang, J. B. Chen, J. Liu, Y. Dai, H. F. Chen, Q. Y. Hu, Z. Wu, J. Z. Zeng, X. S. Yao and X. K. Zhang, *Oncogene*, 2012, **31**(21), 2653–2667.
- 23 L. Hao, J. Luan, D. Zhang, C. Li, H. Guo, L. Qi, X. Liu, T. Li and Q. Zhang, *Colloids Surf., B*, 2014, **117**, 258–266.
- 24 B. Liang, X. Song, G. Liu, R. Li, J. Xie, L. Xiao, M. Du, Q. Zhang, X. Xu and X. Gan, *Exp. Cell Res.*, 2007, **313**, 2833–2844.
- 25 P. C. Lin, Y. L. Chen, S. C. Chiu, Y. L. Yu, S. P. Chen, M. H. Chien, K. Y. Chen, W. L. Chang, S. Z. Lin and T. W. Chiou, *J. Neurochem.*, 2008, **106**, 1017–1026.
- 26 S. Liu, H. Yu, S. M. Kumar, J. S. Martin, Z. Bing, W. Sheng, M. Bosenberg and X. Xu, *Cancer Biol. Ther.*, 2011, **12**, 1005–1014.
- 27 M. Z. Zhang, N. Mulholland, D. Beattie, D. Irwin, Y. C. Gu, Q. Chen, G. F. Yang and J. Clough, *Eur. J. Med. Chem.*, 2013, **63**, 22–32.
- 28 M. Z. Zhang, Q. Chen and G. F. Yang, *Eur. J. Med. Chem.*, 2015, **89**, 421–441.
- 29 R. Álvarez, P. Puebla, J. F. Díaz, A. C. Bento, R. García-Navas, J. de la Iglesia-Vicente, F. Mollinedo, J. M. Andreu, M. Medarde and R. Peláez, *J. Med. Chem.*, 2013, **56**, 2813–2827.
- 30 M. Nguyen, R. C. Marcellus, A. Roulston, M. Watson, L. Serfass, S. R. M. Madiraju, D. Goulet, J. Viallet, L. Belec, X. Billot, S. Acoca, E. Purisima, A. Wiegmanns, L. Cluse, R. W. Johnstone, P. Beauparlant and G. C. Shore, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **104**, 19512–19517.
- 31 O. I. Parisi, C. Morelli, L. Scrivano, M. S. Sinicripi, M. G. Cesario, S. Candamano, F. Puoci and D. Sisci, *RSC Adv.*, 2015, **5**, 65308–65315.
- 32 H. Y. Hu, X. D. Yu, F. Wang, C. R. Lin, J. Z. Zeng, Y. K. Qiu, M. J. Fang and Z. Wu, *Molecules*, 2016, **21**, 530.
- 33 T. H. Maugh, *Science*, 1979, **206**, 1058–1060.
- 34 T. A. Blanpied, R. J. Clarke and J. W. Johnson, *J. Neurosci.*, 2005, **25**, 3312–3322.
- 35 M. W. Robinson, J. H. Overmeyer, A. M. Young, P. W. Erhardt and W. A. Maltese, *J. Med. Chem.*, 2012, **55**, 1940–1956.
- 36 L. L. Yang, G. B. Li, S. Ma, C. Zou, S. Zhou, Q. Z. Sun, C. Cheng, X. Chen, L. J. Wang, S. Feng, L. L. Li and S. Y. Yang, *J. Med. Chem.*, 2013, **56**, 1641–1655.
- 37 J. Yao, J. Chen, Z. He, W. Sun and W. Xu, Design, synthesis and biological activities of thiourea containing sorafenib analogs as antitumor agents, *Bioorg. Med. Chem.*, 2012, **20**(9), 2923–2929.
- 38 Y. C. Duan, Y. C. Zheng, X. C. Li, M. M. Wang, X. W. Ye, Y. Y. Guan, G. Z. Liu, J. X. Zheng and H. M. Liu, *Eur. J. Med. Chem.*, 2013, **64**, 99–110.
- 39 M. Hassan, H. Watari, A. AbuAlmaaty, Y. Ohba and N. Sakuragi, *BioMed Res. Int.*, 2014, 1–23.
- 40 Y. Han, X. Cao, B. Lin, F. Lin, S. Kolluri, J. Stebbins, J. Reed, M. Dawson and X. Zhang, *Oncogene*, 2006, **25**, 2974–2986.
- 41 W. L. DeLano, *The PyMOL Molecular Graphics System*, 2002.
- 42 *Schrödinger Release 2016-1: Maestro*, Schrödinger, LLC, New York, NY, 2016.

